US4483922A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inactivation of enzymes
Assignee: AMF Inc
•
Filing: 1982-05-14
•
Granted: 1984-11-20
•
Expires: 2002-05-14
Abstract
Abstract A method for inactivating enzymes, particularly enzymes found in human serum. The method comprises reacting the enzyme in a suitable medium, e.g. human serum, with an inactivating amount of peracetic acid. In the preferred embodiment the treated serum is subsequently neutralized and dialyzed. Preferably, the serums are used as standards for calibration or as a control in assay kits, e.g. RIA, and EIA or enzyme kits, for the determination of specific ligands and enzymes.
Inventors
- 👤 Charles R. Carpenter
- 👤 Robert H. Dodge
- 👤 Kenneth A. Rosanoff
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 14:35
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/96; C; C12; C12N; C12N9/00; C12N9/0004; C12N9/0006; C12N9/10; C12N9/1025; C12N9/104; C12N9/14; C12N9/16; C12N9/48; C12N9/50; C12N9/64; C12N9/99; C12Y; C12Y101/00; C12Y101/01; C12Y101/01027; C12Y203/00; C12Y203/02; C12Y203/02002; C12Y207/00; C12Y207/03; C12Y207/03002; C12Y301/00; C12Y301/03; C12Y301/03001; G01N2333/00; G01N2333/435; G01N2333/575; G01N2333/595; G01N2333/62; G01N2333/665; G01N2333/695; G01N2496/00; G01N2496/05
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
101 words
A method of reducing enzyme activity in a serum with a minimum effect on other constituents in the serum comprising contacting the serum with an enzyme inactivating amount of a peracetic acid to produce a treated serum, wherein the inactivating amount is from about 0.2% to about 1% peracetic acid by weight of serum, wherein said serum does not degrade an amount of enzyme sensitive labile peptide mixed therein for at least about 96 hours, and wherein the enzymes are selected from the group consisting of: alkaline phosphatase, proteases, gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), creatinin phosphokinase (CPK), and lipase.
Claim 2
Independent Claim
101 words
A method of reducing enzyme activity in a serum with a minimum effect on other constituents in the serum comprising contacting the serum with an enzyme inactivating amount of a peracetic acid to produce a treated serum, wherein the inactivating amount is from about 0.2% to about 1% peracetic acid by weight of serum, wherein said serum does not degrade an amount of enzyme sensitive labile peptide mixed therein for at least about 96 hours, and wherein the enzymes are selected from the group consisting of: alkaline phosphatase, proteases, gamma glutamyl transpeptidase (GGT), lactate dehydrogenase (LDH), creatinin phosphokinase (CPK), and lipase.
Claim 3
Dependent Claim
21 words
The method of claim 1, further comprising neutralizing the treated serum to a physiological normal pH to produce a neutralized serum.
Claim 4
Dependent Claim
11 words
The method of claim 2, further comprising dialyzing the neutralized serum.
Claim 5
Dependent Claim
11 words
The method of claim 1, wherein the serum is human serum.
Claim 6
Dependent Claim
12 words
The method of claim 1, wherein the serum is clarified human serum.
Claim 7
Dependent Claim
22 words
The method of claim 4, wherein the inactivating amount is from about 0.2% to about 0.5% peracetic acid by weight of serum.
Claim 8
Dependent Claim
22 words
The method of claim 2, wherein the treated serum is neutralized with sodium hydroxide to a pH of about 7.4 to 7.8.
Claim 9
Dependent Claim
20 words
The method of claim 2, wherein the treated serum is neutralized with sodium hydroxide to a pH of about 7.4.
Claim 10
Dependent Claim
11 words
The method of claim 1, wherein the enzyme is alkaline phosphatase.
Claim 11
Dependent Claim
13 words
The method of claim 1, wherein the enzyme is gamma glutamyl transpeptidase (GGT).
Claim 12
Dependent Claim
12 words
The method of claim 1, wherein the enzyme is lactate dehydrogenase (LDH).
Claim 13
Dependent Claim
10 words
The method of claim 1, wherein the enzyme is lipase.
Claim 14
Dependent Claim
11 words
The method of claim 1, wherein the labile peptide is gastrin.
Claim 15
Dependent Claim
11 words
The method of claim 1, wherein the labile peptide is insulin.
Claim 16
Dependent Claim
13 words
The method of claim 1, wherein the labile peptide is adenocorticotrophic hormone (ACTH).
References Cited (Backward Citations)
US4311791A
Cited
US4279994A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-11-20 | 1988-05-21 | 1988-11-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-11-20 | 1992-05-21 | 1992-11-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-11-20 | 1996-05-21 | 1996-11-20 | $7700.00 | Window Closed / Lapsed |